Loading...
•
Dec 31, 2025
Nuvation Bio Q4 2025 Earnings Report
Nuvation Bio reported fourth quarter 2025 financial results and provided a business update.
Key Takeaways
Nuvation Bio saw significant growth in the fourth quarter of 2025, driven by the rapid adoption of IBTROZI with 216 new patient starts. Total revenue reached $41.9 million, bolstered by a $25 million milestone payment from Nippon Kayaku. While the company continues to operate at a net loss, it maintains a strong liquidity position with over $529 million in cash and marketable securities to fund its expanding oncology pipeline.
Successfully started 216 new patients on IBTROZI in Q4 2025, totaling 432 since the June launch.
Entered an exclusive licensing agreement with Eisai for taletrectinib in Europe and other global territories in January 2026.
Received a $25 million milestone payment from Nippon Kayaku following reimbursement price establishment in Japan.
Advanced safusidenib into the pivotal Phase 3 SIGMA trial for IDH1-mutant glioma following positive Phase 2 results.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Nuvation Bio intends to build upon the U.S. launch of IBTROZI and progress its clinical pipeline, specifically the Phase 3 SIGMA trial for safusidenib.
Positive Outlook
- Partnering with Eisai to expand IBTROZI's global reach.
- IBTROZI adoption rate is approximately six times greater than prior recent ROS1 TKI launches.
- Taletrectinib included in China’s National Reimbursement Drug List effective January 1, 2026.
- Strong cash position of $529.2 million to support operations.
- Positive Phase 2 data for safusidenib supports its transition to a pivotal Phase 3 trial.
Challenges Ahead
- Continued operating losses as the company scales commercial and R&D efforts.
- Increased SG&A expenses due to higher headcount and marketing costs.
- Potential for hepatotoxicity and other severe adverse reactions associated with IBTROZI.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...